IRVINE, Calif.--(BUSINESS WIRE)--Jan. 18, 2006--Somanta, Inc., a privately held oncology company, today announced the presentation of positive results in tests of cytoxicity and inhibition of pan-cell cycle progression using Alchemix, the Company’s novel alkylating anthraquinone, in a poster session at the 16th International Prostate Cancer Update Conference, Beaver Creek, Colorado. Tests were conducted to study the effect of Alchemix on cell cycle events and in vitro activity. DNA content and Cyclin B1 expression were measured using flow cytometry and a p53 functional human osteosarcoma cell line (U2-OS). The results as contained in the poster presentation indicate:
